Luckenbach T, Burkhardt-Medicke K
Front Pharmacol. 2024; 15:1426040.
PMID: 39166110
PMC: 11333832.
DOI: 10.3389/fphar.2024.1426040.
Xia D, Zhou F, Esser L
Cancer Drug Resist. 2022; 2(3):471-489.
PMID: 35582581
PMC: 8992534.
DOI: 10.20517/cdr.2019.22.
Saaby L, Trasborg J, Rasmussen M, Holst B, Brodin B
Pharmaceutics. 2020; 12(7).
PMID: 32708885
PMC: 7408396.
DOI: 10.3390/pharmaceutics12070673.
Iyoda T, Nagamine Y, Nakane Y, Tokita Y, Akari S, Otsuka K
PLoS One. 2016; 11(9):e0162525.
PMID: 27622612
PMC: 5021278.
DOI: 10.1371/journal.pone.0162525.
Callaghan R
Biochem Soc Trans. 2015; 43(5):995-1002.
PMID: 26517914
PMC: 4613492.
DOI: 10.1042/BST20150131.
ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.
Choi Y, Yu A
Curr Pharm Des. 2013; 20(5):793-807.
PMID: 23688078
PMC: 6341993.
DOI: 10.2174/138161282005140214165212.
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.
Levine A, Noy A, Lee J, Tam W, Ramos J, Henry D
J Clin Oncol. 2012; 31(1):58-64.
PMID: 23169503
PMC: 3530691.
DOI: 10.1200/JCO.2012.42.4648.
Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans.
Jin M, Oldham M, Zhang Q, Chen J
Nature. 2012; 490(7421):566-9.
PMID: 23000902
PMC: 3482266.
DOI: 10.1038/nature11448.
Mutagenesis of the putative nucleotide-binding domains of the multidrug resistance associated protein (MRP). Analysis of the effect of these mutations on MRP mediated drug resistance and transport.
CENTER M, Zhu Q, Sun H
Cytotechnology. 2008; 27(1-3):61-9.
PMID: 19002783
PMC: 3449567.
DOI: 10.1023/A:1008079813339.
Molecular analysis of the multidrug transporter, P-glycoprotein.
Germann U, Chambers T
Cytotechnology. 2008; 27(1-3):31-60.
PMID: 19002782
PMC: 3449557.
DOI: 10.1023/A:1008023629269.
HERG1 currents in native K562 leukemic cells.
Cavarra M, Del Monaco S, Assef Y, Ibarra C, Kotsias B
J Membr Biol. 2007; 219(1-3):49-61.
PMID: 17763876
DOI: 10.1007/s00232-007-9060-x.
Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis.
Barakat S, Gayet L, Dayan G, Labialle S, Lazar A, Oleinikov V
Biochem J. 2005; 388(Pt 2):563-71.
PMID: 15693753
PMC: 1138964.
DOI: 10.1042/BJ20041999.
Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells.
Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S
Br J Pharmacol. 2004; 143(3):379-87.
PMID: 15351776
PMC: 1575343.
DOI: 10.1038/sj.bjp.0705804.
Intracellular xenobiotic concentration as a key factor of cytotoxicity: role of P-glycoprotein.
Simonova V, Samusenko A, Polosukhina E, Baryshnikov A, Shtil A
Dokl Biol Sci. 2004; 394:90-3.
PMID: 15088414
DOI: 10.1023/b:dobs.0000017139.24169.fe.
Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.
Safa A
Curr Med Chem Anticancer Agents. 2004; 4(1):1-17.
PMID: 14754408
PMC: 4447203.
DOI: 10.2174/1568011043482142.
Structural and functional analysis of an amplification containing a PGPA gene in a glucantime-resistant Leishmania (Viannia) guyanensis cell line.
Anacleto C, Abdo M, Ferreira A, Murta S, Romanha A, Fernandes A
Parasitol Res. 2003; 90(2):110-8.
PMID: 12756544
DOI: 10.1007/s00436-002-0798-x.
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H
Cancer Sci. 2003; 94(1):15-21.
PMID: 12708468
PMC: 11160265.
DOI: 10.1111/j.1349-7006.2003.tb01345.x.
Different effects of FK317 on multidrug-resistant tumor in vivo and in vitro.
Naoe Y, Inami M, TAKAGAKI S, Matsumoto S, Kawamura I, Nishigaki F
Jpn J Cancer Res. 1998; 89(10):1047-54.
PMID: 9849584
PMC: 5921702.
DOI: 10.1111/j.1349-7006.1998.tb00495.x.
Reversal of vinblastine transport by chlorpromazine in membrane vesicles from multidrug-resistant human CCRF-CEM leukaemia cells.
Syed S, Christopherson R, Roufogalis B
Br J Cancer. 1998; 78(3):321-7.
PMID: 9703277
PMC: 2063016.
DOI: 10.1038/bjc.1998.493.
P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity.
Mechetner E, Schott B, MORSE B, Stein W, Druley T, Davis K
Proc Natl Acad Sci U S A. 1997; 94(24):12908-13.
PMID: 9371774
PMC: 24237.
DOI: 10.1073/pnas.94.24.12908.